+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Doxorubicin - Global Market Trajectory & Analytics

  • ID: 5302837
  • Report
  • May 2021
  • Region: Global
  • Global Industry Analysts, Inc

Global Doxorubicin Market to Reach US$1.4 Billion by the Year 2027


Amid the COVID-19 crisis, the global market for Doxorubicin estimated at US$992.8 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$313.8 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lung Cancer segment is readjusted to a revised 6.9% CAGR for the next 7-year period. This segment currently accounts for a 16.5% share of the global Doxorubicin market.

The U.S. Accounts for Over 40.6% of Global Market Size in 2020, While China is Forecast to Grow at a 7.5% CAGR for the Period of 2020-2027


The Doxorubicin market in the U.S. is estimated at US$402.7 Million in the year 2020. The country currently accounts for a 40.56% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$113.8 Million in the year 2027 trailing a CAGR of 7.5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 5.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$113.8 Million by the year 2027.

Ovarian Cancer Segment Corners a 14.6% Share in 2020


In the global Ovarian Cancer segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$122.9 Million in the year 2020 will reach a projected size of US$155.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$99.6 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 59 Featured) -

  • Accord Healthcare
  • Allergan Inc.
  • Baxter International Inc.
  • Cadila Pharmaceuticals
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson
  • Meiji Seika Pharma Co.
  • Merrimack Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • SRS Pharmaceuticals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals
  • Thymoorgan Pharmazie GmbH
  • Zydus Cadila
Note: Product cover images may vary from those shown


I. METHODOLOGY


II. EXECUTIVE SUMMARY


1. MARKET OVERVIEW

  • Cancer - An Insight
  • Cancer Treatment
  • Chemotherapy: An Overview
  • An Introduction to Doxorubicin - A Chemotherapy Drug
  • Impact of Covid-19 and a Looming Global Recession
  • EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • COVID-19 Impact on Global Doxorubicin Market
  • GLOBAL MARKET OVERVIEW
  • Global Doxorubicin Market Set to Witness Rapid Growth
  • US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
  • Breast Cancer Constitutes the Largest Application for Doxorubicin
  • Competition
  • New Entrants Seek Opportunities
  • Recent Market Activity


2. FOCUS ON SELECT PLAYERS


3. MARKET TRENDS & DRIVERS

  • Rise in Cancer Incidence to Drive Market Growth
  • EXHIBIT 2: Breakdown of Total Number of Cancer Cases by Region: 2020
  • EXHIBIT 3: Breakdown of Total Number of Cancer Cases by Type: 2020
  • EXHIBIT 4: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Liposomal Delivery Systems Offer Significant Benefits
  • A Review of Liposomal-Doxorubicin Preparations
  • DOX Hydrochloride
  • Ageing Demographics to Drive Demand
  • EXHIBIT 5: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • EXHIBIT 6: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Market to Gain from Rise in Number of Breast Cancer Cases
  • Select Doxorubicin Phase IV and Phase III Completed Clinical Trials for Breast Cancer with Results: As of Dec 30, 2019
  • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
  • EXHIBIT 7: Age-Standardized Lung Cancer Rates for Select Countries
  • Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
  • Uptrend in Healthcare Spending Drives the Doxorubicin Demand
  • EXHIBIT 8: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • EXHIBIT 9: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
  • Cancer Research Spending Continues to Witness Growth
  • EXHIBIT 10: Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • EXHIBIT 11: NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
  • A Netherland's Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect (2020) (The Netherlands)
  • Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
  • Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
  • Combination Therapy: A Double Whammy Success


4. GLOBAL MARKET PERSPECTIVE


III. MARKET ANALYSIS


UNITED STATES

  • Market Analysis
  • Rising Cancer Cases Spur Growth in Doxorubicin Market
  • EXHIBIT 12: Estimated Number of New Cancer Cases and Deaths in the US (2019)
  • EXHIBIT 13: Number of FDA-Approved Oncology Drugs in the US (2010-2018)
  • EXHIBIT 14: Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
  • EXHIBIT 15: Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
  • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
  • Market Analytics


CANADA

  • EXHIBIT 16: Number of New Cancer Cases in Canada: 2019
  • Market Analytics


JAPAN


CHINA

  • EXHIBIT 17: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
  • Market Analytics


EUROPE

  • Market Analysis
  • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
  • EXHIBIT 18: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • EXHIBIT 19: Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
  • Market Analytics


FRANCE


GERMANY


ITALY


UNITED KINGDOM


SPAIN


RUSSIA


REST OF EUROPE


ASIA-PACIFIC

  • Market Analysis
  • An Insight into Asia-Pacific Market for Doxorubicin
  • EXHIBIT 20: Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
  • Market Analytics


AUSTRALIA


INDIA

  • Market Analysis
  • Market Analytics


SOUTH KOREA


REST OF ASIA-PACIFIC


LATIN AMERICA


ARGENTINA


BRAZIL


MEXICO


REST OF LATIN AMERICA


MIDDLE EAST


IRAN


ISRAEL


SAUDI ARABIA


UNITED ARAB EMIRATES


REST OF MIDDLE EAST


AFRICA


IV. COMPETITION

  • Total Companies Profiled: 59

Note: Product cover images may vary from those shown
Adroll
adroll